Efficacy of stem cell in improvement of left ventricular function in acute myocardial infarction - MI3 Trial
Authors:
Open Access
- 1 January 2015
- journal article
- research article
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 142 (2) , 165-74
Abstract
Background & objectives: Acute myocardial infarction (AMI) is characterized by irreparable and irreversible loss of cardiac myocytes. Despite major advances in the management of AMI, a large number of patients are left with reduced left ventricular ejection fraction (LVEF), which is a major determinant of short and long term morbidity and mortality. A review of 33 randomized control trials has shown varying improvement in left ventricular (LV) function in patients receiving stem cells compared to standard medical therapy. Most trials had small sample size and were underpowered. This phase III prospective, open labelled, randomized multicenteric trial was undertaken to evaluate the efficacy in improving the LVEF over a period of six months, after injecting a predefined dose of 5-10 Χ 10 [8] autologous mononuclear cells (MNC) by intra-coronary route, in patients, one to three weeks post ST elevation AMI, in addition to the standard medical therapy. Methods: In this phase III prospective, multicentric trial 250 patients with AMI were included and randomized into stem cell therapy (SCT) and non SCT groups. All patients were followed up for six months. Patients with AMI having left ventricular ejection fraction (LVEF) of 20-50 per cent were included and were randomized to receive intracoronary stem cell infusion after successfully completing percutaneous coronary intervention (PCI). Results: On intention-to-treat analysis the infusion of MNCs had no positive impact on LVEF improvement of ≥ 5 per cent. The improvement in LVEF after six months was 5.17 ± 8.90 per cent in non SCT group and 4.82 ± 10.32 per cent in SCT group. The adverse effects were comparable in both the groups. On post hoc analysis it was noted that the cell dose had a positive impact when infused in the dose of ≥ 5 X 10 [8] (n=71). This benefit was noted upto three weeks post AMI. There were 38 trial deviates in the SCT group which was a limitation of the study. Interpretation & conclusions:Infusion of stem cells was found to have no benefit in ST elevation AMI. However, the procedure was safe. A possible benefit was seen when the predefined cell dose was administered which was noted upto three weeks post AMI, but this was not significant and needs confirmation by larger trials.Keywords
This publication has 21 references indexed in Scilit:
- Stem cell treatment for acute myocardial infarction2012
- Stem Cell Therapy in Acute Myocardial Infarction: A Pot of Gold or Pandora's BoxStem Cells International, 2011
- Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trialEuropean Heart Journal, 2010
- Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells: a 3 year serial echocardiographic sub-study of the randomized-controlled ASTAMI studyEuropean Heart Journal - Cardiovascular Imaging, 2010
- Bone Marrow Cell Transplantation Improves Cardiac, Autonomic, and Functional Indexes in Acute Anterior Myocardial Infarction Patients (Cardiac Study)European Journal of Heart Failure, 2010
- The BALANCE StudyJACC, 2009
- Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) TrialEuropean Heart Journal, 2009
- Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry dataThe Lancet, 2008
- Adult Bone Marrow–Derived Cells for Cardiac RepairArchives of internal medicine (1960), 2007
- Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trialEuropean Heart Journal, 2006